Udenyca Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
1
Udenyca General Information
Description
Portfolio of a pharmaceutical drug designed to stimulate white blood cell production. The company offers a medication to help cancer patients recover from chemotherapy-induced neutropenia, enabling them to better tolerate treatment and reduce the risk of infection.
Contact Information
Website
www.udenyca.comCorporate Office
- United States
Corporate Office
- United States
Udenyca Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Udenyca Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Udenyca FAQs
-
Where is Udenyca headquartered?
Udenyca is headquartered in .
-
What industry is Udenyca in?
Udenyca’s primary industry is Buildings and Property.
-
Is Udenyca a private or public company?
Udenyca is a Private company.
-
What is the current valuation of Udenyca?
The current valuation of Udenyca is .
-
What is Udenyca’s current revenue?
The current revenue for Udenyca is .
-
Who are Udenyca’s investors?
Coherus Oncology has invested in Udenyca.
-
When was Udenyca acquired?
Udenyca was acquired on 11-Apr-2025.
-
Who acquired Udenyca?
Udenyca was acquired by Intas Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process